Immunosuppressants: Organ Transplant Medication Guide

Living With Immunosuppression After Transplant

Organ transplantation is one of medicine's greatest achievements — extending and saving the lives of over 40,000 Americans annually. But the transplanted organ is recognized as "foreign" by the immune system, which will attack and destroy it without continuous immunosuppression.

This creates a fundamental tension: enough immunosuppression to prevent rejection, but not so much that serious infections or malignancies develop. Managing this balance, with complex medicine regimens, medicine level monitoring, and lifelong vigilance, is the central challenge of transplant medicine.

---

The Immune Response to Transplant

When a donor organ is transplanted, recipient T-lymphocytes recognize foreign HLA (human leukocyte antigen) molecules on donor cells — the primary trigger for rejection. Three types of rejection occur at different timepoints:

• Hyperacute rejection: Minutes to hours; pre-formed antibodies; prevented by crossmatch testing before transplant
• Acute rejection: Days to months; T-cell mediated; the target of standard immunosuppression; treatable if caught early
• Chronic rejection: Months to years; gradual fibrosis and vasculopathy; less treatment-responsive; major cause of long-term graft loss

---

Induction Therapy (Peri-Transplant)

High-intensity immunosuppression is used at the time of transplant to prevent early acute rejection:

Depleting agents (T-cell):

• Antithymocyte globulin (ATG — Thymoglobulin): Polyclonal antibody depleting T cells; used in high-rejection-risk patients; associated with post-transplant lymphoproliferative disorder (PTLD) risk
• Alemtuzumab (Campath): Anti-CD52 monoclonal antibody; profound lymphocyte depletion; used in some protocols

Non-depleting agents:

• Basiliximab (Simulect): Anti-IL-2 receptor (CD25) antibody; blocks T-cell activation without depletion; lower infectious risk; standard for kidney transplant

---

Maintenance Immunosuppression: The Triple Regimen

Most solid organ transplant recipients receive a three-medicine maintenance regimen:

1. Calcineurin Inhibitors (CNIs) — Backbone

Tacrolimus (Prograf, Astagraf XL, Envarsus XR):

• Most widely used CNI worldwide; replaced cyclosporine as first-line in most transplant types
• Mechanism: Binds FKBP12 → inhibits calcineurin → blocks IL-2 production → T-cell activation blocked
• Narrow therapeutic index — requires trough level monitoring (target varies by organ, time post-transplant: typically 8-12 ng/mL early, 5-8 ng/mL later for kidney)
• Nephrotoxicity — most important long-term toxicity; contributes to chronic kidney disease even in non-kidney transplants
• Neurotoxicity — tremor, headache, posterior reversible encephalopathy syndrome (PRES)
• Metabolic effects — diabetes (new-onset diabetes after transplant, NODAT), hypertension, hyperlipidemia
• CYP3A4/P-gp substrate — massive medicine interaction potential (azole antifungals, macrolides, rifampin, St. John's Wort)

Cyclosporine (Neoral, Sandimmune):

• Original CNI; still used in some protocols; also narrow therapeutic index
• More hypertension, hyperlipidemia, and gingival hyperplasia than tacrolimus
• Less nephrotoxicity at equivalent immunosuppression levels (debated)

2. Antimetabolites — Adjuncts

Mycophenolate mofetil (CellCept) / mycophenolic acid (Myfortic):

• Most widely used antimetabolite; blocks de novo purine synthesis → inhibits lymphocyte proliferation
• Preferred over azathioprine in most modern protocols
• GI toxicity — diarrhea, nausea most common; Myfortic (enteric-coated) may reduce GI effects
• Teratogenic — absolute contraindication in pregnancy; reliable contraception mandatory
• Myelosuppression — dose-dependent; monitor CBC

Azathioprine (Imuran):

• Older antimetabolite; 6-mercaptopurine prodrug
• TPMT/NUDT15 testing recommended to identify patients at risk for severe myelosuppression
• Replaced by mycophenolate in most protocols; still used when mycophenolate intolerance or in special populations

3. Corticosteroids

Prednisone or prednisolone: used at high doses immediately post-transplant, then tapered to low maintenance doses (5-10 mg/day) or completely withdrawn (steroid minimization/avoidance protocols).

Long-term steroid toxicities drive steroid-avoidance strategies: diabetes, hypertension, osteoporosis, weight gain, cataracts, adrenal suppression, avascular necrosis.

---

mTOR Inhibitors (Alternative/Add-On)

Sirolimus (Rapamune) and Everolimus (Zortress/Certican):

• Block mTOR → inhibit T-cell proliferation (different pathway than CNIs)
• Lower nephrotoxicity than CNIs — sometimes used to minimize or replace CNI in patients with CNI-related kidney dysfunction
• Unique toxicities: Impaired wound healing (avoid peri-transplant), hyperlipidemia, proteinuria, interstitial pneumonitis, oral ulcers, lymphedema
• Trough level monitoring required (sirolimus: 4-12 ng/mL)
• Everolimus also used in oncology (renal cell carcinoma, breast cancer)

---

Rejection Treatment

Acute cellular rejection: High-dose IV methylprednisolone (pulse steroids) for 3-5 days; response in ~75% Steroid-refractory rejection: ATG depletion therapy Antibody-mediated rejection (AMR): More difficult; plasmapheresis, IVIG, rituximab, eculizumab